Last updated on February 2018

Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

Brief description of study

The purpose of this study is to assess whether dasatinib can be discontinued without occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in complete molecular remission (CMR) while on dasatinib.

Clinical Study Identifier: NCT01627132

Find a site near you

Start Over

Nippon Medical School

Sendagi 1-1-5, Japan
  Connect »